Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
暂无分享,去创建一个
Simon Smale | Ken Takeuchi | B. Thjódleifsson | E. Bjornsson | I. Bjarnason | R. Sherwood | P. Premchand | S. Smale | Purushothaman Premchand | K. Takeuchi | Einar Bjornsson | Ingvar Bjarnason | Laurence Maiden | Roy Sherwood | Bjarni Thjodleifsson | L. Maiden
[1] G. Bonner,et al. A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.
[2] S. Targan,et al. The Spectrum of Gastrointestinal Toxicity and Effect on Disease Activity of Selective Cyclooxygenase-2 Inhibitors in Patients with Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.
[3] R. Langenbach,et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. , 2004, Gastroenterology.
[4] C. Hawkey,et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis , 2004, Alimentary pharmacology & therapeutics.
[5] C. Patrono,et al. Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects , 2004, Circulation.
[6] I. Bjarnason,et al. The G.U.T. of gut , 2004, Scandinavian journal of gastroenterology.
[7] J. Wallace,et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[8] R. Botting. COX-1 and COX-3 inhibitors. , 2003, Thrombosis research.
[9] R. Modigliani,et al. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib. , 2002 .
[10] I. Forgacs,et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.
[11] W. Sandborn,et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. , 2002 .
[12] I. Bjarnason,et al. Inflammatory bowel disease and spondylarthropathy. , 2001, Arthritis and rheumatism.
[13] G. Bonner. Exacerbation of inflammatory bowel disease associated with use of celecoxib. , 2001 .
[14] O. Kronborg,et al. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. , 2001, Scandinavian journal of gastroenterology.
[15] B. Thjódleifsson,et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen , 2001, Gut.
[16] B. Thjódleifsson,et al. A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.
[17] J. Wallace,et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. , 2000, Gastroenterology.
[18] L. Kitchen,et al. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease , 2000, American Journal of Gastroenterology.
[19] B. Korelitz,et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study , 2000, American Journal of Gastroenterology.
[20] I. Bjarnason,et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.
[21] A. Püspök,et al. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon , 2000, Diseases of the colon and rectum.
[22] R. Lorenz,et al. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen , 1999, Nature Medicine.
[23] J. Vane,et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Wolfe,et al. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.
[25] J. Evans,et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. , 1997, Gut.
[26] J. Wrigglesworth,et al. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. , 1996, Arthritis and rheumatism.
[27] D. Kelleher,et al. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. , 1996, Gut.
[28] A. Macpherson,et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. , 1993, Gastroenterology.
[29] A. Røseth,et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. , 1992, Scandinavian journal of gastroenterology.
[30] H. Kaufmann,et al. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. , 1987, Annals of internal medicine.
[31] A. Levi,et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. , 1986, Gut.
[32] K. Ewe,et al. European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .
[33] D. Rampton,et al. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. , 1983, Gut.
[34] D. Rampton,et al. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. , 1981, Postgraduate medical journal.
[35] D. Rampton,et al. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. , 1981, Prostaglandins.
[36] R. F. Harvey,et al. A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.
[37] A. Thomson. NSAID-Induced Gastric Damage in Rats , 2001 .
[38] A. Røseth,et al. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.
[39] R. Simpson,et al. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat. , 1998, Scandinavian journal of gastroenterology.
[40] J. Vane,et al. Aspirin and Other Salicylates , 1993 .
[41] G. Labó,et al. Prostaglandins, indomethacin, and ulcerative colitis , 1980 .